[go: up one dir, main page]

DK3068406T3 - Gensidigt prodrug omfattende kortkædede fedtsyrer og zebularin eller 1'-cyano-cytarabin til kræftbehandling - Google Patents

Gensidigt prodrug omfattende kortkædede fedtsyrer og zebularin eller 1'-cyano-cytarabin til kræftbehandling Download PDF

Info

Publication number
DK3068406T3
DK3068406T3 DK14862419.0T DK14862419T DK3068406T3 DK 3068406 T3 DK3068406 T3 DK 3068406T3 DK 14862419 T DK14862419 T DK 14862419T DK 3068406 T3 DK3068406 T3 DK 3068406T3
Authority
DK
Denmark
Prior art keywords
zebularin
cytarabine
cyano
cancer treatment
including short
Prior art date
Application number
DK14862419.0T
Other languages
English (en)
Inventor
Sunmi Shin
Hyangmi Kim
Su-Sung Oh
Original Assignee
Kainos Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kainos Medicine Inc filed Critical Kainos Medicine Inc
Application granted granted Critical
Publication of DK3068406T3 publication Critical patent/DK3068406T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/067Pyrimidine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14862419.0T 2013-11-14 2014-11-14 Gensidigt prodrug omfattende kortkædede fedtsyrer og zebularin eller 1'-cyano-cytarabin til kræftbehandling DK3068406T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904064P 2013-11-14 2013-11-14
PCT/KR2014/010972 WO2015072784A1 (en) 2013-11-14 2014-11-14 Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment

Publications (1)

Publication Number Publication Date
DK3068406T3 true DK3068406T3 (da) 2020-03-30

Family

ID=53057653

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14862419.0T DK3068406T3 (da) 2013-11-14 2014-11-14 Gensidigt prodrug omfattende kortkædede fedtsyrer og zebularin eller 1'-cyano-cytarabin til kræftbehandling

Country Status (14)

Country Link
US (1) US10500224B2 (da)
EP (1) EP3068406B1 (da)
JP (1) JP6215484B2 (da)
KR (1) KR101869940B1 (da)
CN (1) CN105705150B (da)
AU (1) AU2014349328A1 (da)
BR (1) BR112016008934B1 (da)
CA (1) CA2926909A1 (da)
DK (1) DK3068406T3 (da)
ES (1) ES2778524T3 (da)
HU (1) HUE048844T2 (da)
MX (1) MX2016005900A (da)
PL (1) PL3068406T3 (da)
WO (1) WO2015072784A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016195353A1 (en) * 2015-06-01 2016-12-08 Kainos Medicine, Inc. A use of 1'-cyano-cytarabine for cancer treatment
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
RU2748103C1 (ru) * 2019-12-13 2021-05-19 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Средство для ингибирования фермента тирозил-ДНК-фосфодиэстеразы 1 человека на основе производных пентафуранозилнуклеозидов
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
WO2024169774A2 (en) * 2023-02-17 2024-08-22 Ascletis BioScience Co., Ltd Nucleoside and nucleotide analogs, methods of making and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1297398A (da) * 1969-08-06 1972-11-22
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
JPH07109289A (ja) 1993-08-18 1995-04-25 Yamasa Shoyu Co Ltd 1’位炭素置換ピリミジンヌクレオシドおよびその製造法
EP1418949B1 (en) 2001-07-31 2013-06-19 THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF OREGON Inhibitor of dna methylation
WO2012008845A1 (en) 2010-07-13 2012-01-19 Clavis Pharma Asa Parenteral formulations of elacytarabine derivatives

Also Published As

Publication number Publication date
KR20160079886A (ko) 2016-07-06
CN105705150A (zh) 2016-06-22
JP2016540829A (ja) 2016-12-28
US10500224B2 (en) 2019-12-10
EP3068406A1 (en) 2016-09-21
ES2778524T3 (es) 2020-08-10
BR112016008934A2 (da) 2017-08-01
AU2014349328A1 (en) 2016-06-30
HUE048844T2 (hu) 2020-12-28
EP3068406A4 (en) 2017-04-12
KR101869940B1 (ko) 2018-06-21
WO2015072784A1 (en) 2015-05-21
CA2926909A1 (en) 2015-05-21
US20160228562A1 (en) 2016-08-11
MX2016005900A (es) 2016-07-13
EP3068406B1 (en) 2020-01-08
BR112016008934B1 (pt) 2022-11-08
JP6215484B2 (ja) 2017-10-18
PL3068406T3 (pl) 2020-08-10
CN105705150B (zh) 2021-03-23

Similar Documents

Publication Publication Date Title
IL259795A (en) Methods and compositions for treating a serpinc1-associated disorder
DK3294770T4 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
DK3142637T3 (da) Keratin treatment formulations and methods
HUE053903T2 (hu) Kombinációs terápia rák ellen
HUE054012T2 (hu) Kombinációs terápia rák ellen
PL3265053T3 (pl) Sposoby leczenia skóry
HUE059694T2 (hu) Készítmény rák kezelésére
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
DK3035955T3 (da) Sammensætning og vaccine til behandling af lungekræft
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
IL251215B (en) Cannabinoid composition and method for treating pain
IL260684B (en) Treatment for modulating gut microbiota
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
BR112015028115A2 (pt) métodos e composições para o tratamento de câncer
IL247354A0 (en) Treatment of conditions associated with hyperinsulinaemia
DK3122332T3 (da) Opløselige mikronåle til hudbehandling
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
HRP20190088T1 (hr) Ekstrakt iz prirodnog indiga i postupak njegove priprave
EP3215219C0 (en) SKIN TREATMENT SYSTEM
EP3328353A4 (en) TOPICAL SKIN FORMULATIONS
GB201520174D0 (en) Improvements in or relating to medical actuators
DK3083683T3 (da) Sammensætninger og fremgangsmåder til behandling af fedtvævsansamlinger
PT3511004T (pt) Preparações combinadas para o tratamento de cancro
DK2968479T3 (da) Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
IL263863B (en) Double targeted constructs to affect tumor kill